A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom

摘要: Many chemotherapy regimens are used for treating SCLC in the United Kingdom, but it is not known, any detail, which used, by specialists, types of patient. We conducted a survey among all medical and clinical oncologists, respiratory physicians general with interest Kingdom to find out. The questionnaire asked number patients treated annually; how many were given chemotherapy; drugs, doses schedules chosen according prognostic group (as defined clinician); reasons choice regimen. 1214 questionnaires sent out, responses received from 1070 (88%) clinicians; 266 (25%) these chemotherapy. Of 4674 annually, 36% 30% 27% physicians, 7% physicians. In all, 34 reported 151 different combinations dose schedule. 2311 good prognosis patients, 23 commonest being ACE (doxorubicin, cyclophosphamide, etoposide), ICbE (ifosfamide, carboplatin, CAV (cyclophosphamide, doxorubicin, vincristine), CbE (carboplatin, PE (cisplatin, etoposide). 1517 poor 21 CAV, EV (etoposide, CbE, alternating PE, oral etoposide. 452 regardless 219 no criteria specified. remaining 175 second-line or avoid toxicity because intercurrent disease other reasons. main affecting regimen routine local practice, patients' convenience, quality life considerations, trial results cost. show wide variation practice will be useful reporting planning trials deciding on treatment policies.